Vaishali Pharma Ltd. (VAISHALI) Price & Analysis

Compare

1 Followers

VAISHALI Stock Chart & Stats

₹8.04

-₹0.33(-1.95%)

At close: Jan 08 4:00 PM EST

₹8.04

-₹0.33(-1.95%)

Day’s Range― - ―

52-Week Range₹6.02 - ₹15.24

Previous CloseN/A

Volume565.66K

Average Volume (3M)399.32K

Market Cap

₹656.02M

Enterprise Value₹804.78M

Total Cash (Recent Filing)₹10.46M

Total Debt (Recent Filing)₹156.01M

Price to Earnings (P/E)21.3

Beta1.21

Next Earnings

Jun 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.10

Shares Outstanding107,192,130

10 Day Avg. Volume443,817

30 Day Avg. Volume399,324

Financial Highlights & Ratios

PEG Ratio-11.89

Price to Book (P/B)0.26

Price to Sales (P/S)0.17

P/FCF Ratio-0.86

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Consistent Top-line GrowthSustained ~15% revenue growth indicates expanding product uptake or market penetration. Over 2–6 months this supports capacity utilization, scale advantages and potential margin recovery if cost control follows; durable top-line momentum underpins reinvestment and strategic initiatives.

Stable Balance Sheet With Healthy EquityA healthy and growing equity base with moderate debt suggests financial flexibility and lower solvency risk. This stability enables funding for R&D, manufacturing or M&A without excessive leverage, preserving long-term operational resilience through industry cycles.

Positive Net Profit Margin RetainedMaintaining a positive net margin while facing margin pressures shows the business can absorb cost shocks and still deliver bottom-line results. That persistent profitability, even if modest, supports reinvestment and creditor confidence over the medium term.

Bears Say

Negative Operating And Free Cash FlowNegative operating and free cash flow signal the company isn't converting revenue into sustainable cash, risking liquidity for working capital and capex. Over months this constrains investment, forces external financing or asset sales, and weakens execution of growth plans.

Negative EBIT And Declining Gross MarginA negative EBIT and compressing gross margins point to structural cost or pricing pressures that erode operating profitability. Without margin stabilization, profitability recovery is uncertain, making long-term earnings and cash generation vulnerable despite revenue growth.

Declining EPS TrendFalling EPS reflects earnings deterioration per share and may indicate diluted shareholder returns or operational issues. Persisting EPS decline can impair reinvestment capacity, reduce stakeholder confidence and limit ability to attract capital over a multi-month horizon.

Vaishali Pharma Ltd. News

Vaishali Pharma Clarifies Preferential Issue Pricing in NSE-Directed Postal Ballot Corrigendum

Vaishali Pharma Ltd. ( ($IN:VAISHALI) ) has provided an announcement. Vaishali Pharma Ltd. has issued a corrigendum to...

16d ago

Vaishali Pharma’s Equity Shares Approved for Trading on NSE

Vaishali Pharma Ltd. ( ($IN:VAISHALI) ) has shared an update. Vaishali Pharma Limited has announced that it has...

3M ago

Vaishali Pharma Expands Business Scope with MOA Amendment

Vaishali Pharma Ltd. ( ($IN:VAISHALI) ) just unveiled an update. Vaishali Pharma Ltd. has announced an amendment to...

11M ago

Vaishali Pharma Ltd. Announces Key Management Appointments

Vaishali Pharma Ltd. ( ($IN:VAISHALI) ) just unveiled an announcement. Vaishali Pharma Ltd. has announced changes in its...

11M ago

VAISHALI FAQ

What was Vaishali Pharma Ltd.’s price range in the past 12 months?

Vaishali Pharma Ltd. lowest stock price was ₹6.02 and its highest was ₹15.24 in the past 12 months.

What is Vaishali Pharma Ltd.’s market cap?

Vaishali Pharma Ltd.’s market cap is ₹656.02M.

When is Vaishali Pharma Ltd.’s upcoming earnings report date?

Vaishali Pharma Ltd.’s upcoming earnings report date is Jun 03, 2026 which is in 78 days.

How were Vaishali Pharma Ltd.’s earnings last quarter?

Vaishali Pharma Ltd. released its earnings results on Feb 13, 2026. The company reported ₹0.101 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.101.

Is Vaishali Pharma Ltd. overvalued?

According to Wall Street analysts Vaishali Pharma Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Vaishali Pharma Ltd. pay dividends?

Vaishali Pharma Ltd. does not currently pay dividends.

What is Vaishali Pharma Ltd.’s EPS estimate?

Vaishali Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Vaishali Pharma Ltd. have?

Vaishali Pharma Ltd. has 107,192,130 shares outstanding.

What happened to Vaishali Pharma Ltd.’s price movement after its last earnings report?

Vaishali Pharma Ltd. reported an EPS of ₹0.101 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.126%.

Which hedge fund is a major shareholder of Vaishali Pharma Ltd.?

Currently, no hedge funds are holding shares in IN:VAISHALI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Vaishali Pharma Ltd.

Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers active pharmaceutical ingredients (APIs), including antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, anti-diarrheal/anti-protozoal/anti-parasitic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helmintic drugs, as well as excipients, topical steroids, corticosteroids, and enzymes. The company also provides formulation products, such as antibiotics/antibacterial, anti-platelet, laxative, anti-ulcer/enzyme, anti-asthmatic, anti-malarial, anti-cold/anti-allergic/anti-viral, anti-psychotic, anti-fungal, anti-inflammatory/analgesic/anti-pyretic, anti-diabetic, cardiac, vitamins, topical steroids/corticosteroids, and other formulations. In addition, it offers veterinary pharmaceutical, nutraceutical, oncology, herbal, and surgical products. The company was founded in 1989 and is headquartered in Mumbai, India.